vs
Bioceres Crop Solutions Corp.（BIOX）与Evogene Ltd.（EVGN）财务数据对比。点击上方公司名可切换其他公司
Bioceres Crop Solutions Corp.的季度营收约是Evogene Ltd.的24.0倍（$77.6M vs $3.2M）。Bioceres Crop Solutions Corp.净利率更高（-9.6% vs -237.7%，领先228.1%）。Evogene Ltd.同比增速更快（40.7% vs -16.8%）
Bioceres Crop Solutions Corp是一家全球农业科技企业，研发并商业化耐旱种子性状、生物肥料、生物农药等可持续作物增产解决方案，服务南美、北美、欧洲及亚太地区的农户，致力于提升作物产量，同时降低农业生产的环境影响。
Evogene是一家总部位于以色列的计算化学企业，专注于为医药及农业领域提供小分子生成式设计服务。其核心技术为自主研发的生成式AI引擎ChemPass AI，可设计出符合多项关键参数优化要求的新型高活性小分子。该强大平台能大幅提升研发成功率，同时缩短开发周期、降低成本。
BIOX vs EVGN — 直观对比
营收规模更大
BIOX
是对方的24.0倍
$3.2M
营收增速更快
EVGN
高出57.5%
-16.8%
净利率更高
BIOX
高出228.1%
-237.7%
损益表 — Q1 2026 vs Q2 2025
| 指标 | | |
|---|---|---|
| 营收 | $77.6M | $3.2M |
| 净利润 | $-7.4M | $-7.7M |
| 毛利率 | 46.8% | 48.8% |
| 营业利润率 | 9.3% | -189.0% |
| 净利率 | -9.6% | -237.7% |
| 营收同比 | -16.8% | 40.7% |
| 净利润同比 | -20.2% | 22.0% |
| 每股收益（稀释后） | $-0.12 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BIOXEVGN
| Q3 25 | $77.6M | — | ||
| Q2 25 | — | $3.2M | ||
| Q1 25 | $60.6M | — | ||
| Q4 24 | $98.8M | — | ||
| Q3 24 | $93.3M | — | ||
| Q2 24 | — | $2.3M | ||
| Q1 24 | $84.0M | — | ||
| Q4 23 | $140.2M | — |
净利润BIOXEVGN
| Q3 25 | $-7.4M | — | ||
| Q2 25 | — | $-7.7M | ||
| Q1 25 | $-1.6M | — | ||
| Q4 24 | $605.2K | — | ||
| Q3 24 | $-6.2M | — | ||
| Q2 24 | — | $-9.8M | ||
| Q1 24 | $9.8M | — | ||
| Q4 23 | $1.2M | — |
毛利率BIOXEVGN
| Q3 25 | 46.8% | — | ||
| Q2 25 | — | 48.8% | ||
| Q1 25 | 39.4% | — | ||
| Q4 24 | 42.0% | — | ||
| Q3 24 | 40.2% | — | ||
| Q2 24 | — | 71.8% | ||
| Q1 24 | 50.8% | — | ||
| Q4 23 | 36.7% | — |
营业利润率BIOXEVGN
| Q3 25 | 9.3% | — | ||
| Q2 25 | — | -189.0% | ||
| Q1 25 | 1.5% | — | ||
| Q4 24 | 14.5% | — | ||
| Q3 24 | 2.5% | — | ||
| Q2 24 | — | -409.9% | ||
| Q1 24 | 15.7% | — | ||
| Q4 23 | 12.0% | — |
净利率BIOXEVGN
| Q3 25 | -9.6% | — | ||
| Q2 25 | — | -237.7% | ||
| Q1 25 | -2.6% | — | ||
| Q4 24 | 0.6% | — | ||
| Q3 24 | -6.6% | — | ||
| Q2 24 | — | -428.5% | ||
| Q1 24 | 11.6% | — | ||
| Q4 23 | 0.9% | — |
每股收益（稀释后）BIOXEVGN
| Q3 25 | $-0.12 | — | ||
| Q2 25 | — | — | ||
| Q1 25 | $-0.02 | — | ||
| Q4 24 | $0.00 | — | ||
| Q3 24 | $-0.10 | — | ||
| Q2 24 | — | $-1.82 | ||
| Q1 24 | $0.14 | — | ||
| Q4 23 | $0.00 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $15.5M | $8.3M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $288.3M | $12.4M |
| 总资产 | $734.9M | $33.9M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BIOXEVGN
| Q3 25 | $15.5M | — | ||
| Q2 25 | — | $8.3M | ||
| Q1 25 | $38.5M | — | ||
| Q4 24 | $29.2M | — | ||
| Q3 24 | $32.3M | — | ||
| Q2 24 | — | $9.5M | ||
| Q1 24 | $16.4M | — | ||
| Q4 23 | $24.4M | — |
股东权益BIOXEVGN
| Q3 25 | $288.3M | — | ||
| Q2 25 | — | $12.4M | ||
| Q1 25 | $345.0M | — | ||
| Q4 24 | $346.3M | — | ||
| Q3 24 | $346.0M | — | ||
| Q2 24 | — | $19.9M | ||
| Q1 24 | $348.5M | — | ||
| Q4 23 | $335.3M | — |
总资产BIOXEVGN
| Q3 25 | $734.9M | — | ||
| Q2 25 | — | $33.9M | ||
| Q1 25 | $798.2M | — | ||
| Q4 24 | $835.2M | — | ||
| Q3 24 | $827.3M | — | ||
| Q2 24 | — | $41.0M | ||
| Q1 24 | $836.1M | — | ||
| Q4 23 | $819.5M | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $14.4M | $-7.5M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流BIOXEVGN
| Q3 25 | $14.4M | — | ||
| Q2 25 | — | $-7.5M | ||
| Q1 25 | $23.3M | — | ||
| Q4 24 | $-5.4M | — | ||
| Q3 24 | $5.2M | — | ||
| Q2 24 | — | $-9.6M | ||
| Q1 24 | $-17.4M | — | ||
| Q4 23 | $21.1M | — |
现金转化率BIOXEVGN
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -8.85× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -1.78× | — | ||
| Q4 23 | 17.05× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
